Business Description
LeMaitre Vascular Inc
NAICS : 339112
SIC : 3841
ISIN : US5255582018
Share Class Description:
LMAT: Ordinary SharesTotal Employee Number:
655Description
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.94 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | 1.97 | |||||
Interest Coverage | 14.07 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 8.01 | |||||
Beneish M-Score | -2.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.3 | |||||
3-Year EBITDA Growth Rate | 33.5 | |||||
3-Year EPS without NRI Growth Rate | 26.2 | |||||
3-Year FCF Growth Rate | 48.1 | |||||
3-Year Book Growth Rate | 12.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 11.37 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.97 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.37 | |||||
9-Day RSI | 56.64 | |||||
14-Day RSI | 50.71 | |||||
3-1 Month Momentum % | -10.53 | |||||
6-1 Month Momentum % | 17.82 | |||||
12-1 Month Momentum % | 19.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.32 | |||||
Quick Ratio | 12.59 | |||||
Cash Ratio | 11.01 | |||||
Days Inventory | 297.47 | |||||
Days Sales Outstanding | 49.4 | |||||
Days Payable | 18.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.94 | |||||
Dividend Payout Ratio | 0.34 | |||||
3-Year Dividend Growth Rate | 17 | |||||
Forward Dividend Yield % | 1.05 | |||||
5-Year Yield-on-Cost % | 1.91 | |||||
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | -2.94 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.39 | |||||
Operating Margin % | 28.51 | |||||
Net Margin % | 24.35 | |||||
EBITDA Margin % | 37.58 | |||||
FCF Margin % | 30.87 | |||||
OCF Margin % | 34.07 | |||||
ROE % | 16.51 | |||||
ROA % | 10.48 | |||||
ROIC % | 24.75 | |||||
3-Year ROIIC % | 159.57 | |||||
ROC (Joel Greenblatt) % | 69.44 | |||||
ROCE % | 15.22 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 35.26 | |||||
Forward PE Ratio | 31.89 | |||||
PE Ratio without NRI | 38.77 | |||||
Shiller PE Ratio | 63.75 | |||||
Price-to-Owner-Earnings | 32.45 | |||||
PEG Ratio | 2.52 | |||||
PS Ratio | 8.68 | |||||
PB Ratio | 5.37 | |||||
Price-to-Tangible-Book | 7.07 | |||||
Price-to-Free-Cash-Flow | 28.28 | |||||
Price-to-Operating-Cash-Flow | 25.63 | |||||
EV-to-EBIT | 23.38 | |||||
EV-to-EBITDA | 20.83 | |||||
EV-to-Forward-EBITDA | 28.45 | |||||
EV-to-Revenue | 7.83 | |||||
EV-to-Forward-Revenue | 7.18 | |||||
EV-to-FCF | 25.36 | |||||
Price-to-GF-Value | 0.99 | |||||
Price-to-Projected-FCF | 2.47 | |||||
Price-to-DCF (Earnings Based) | 1.83 | |||||
Price-to-DCF (FCF Based) | 1.27 | |||||
Price-to-Median-PS-Value | 1.28 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.73 | |||||
Price-to-Graham-Number | 3.49 | |||||
| Price-to-Net-Current-Asset-Value | 8.56 | |||||
| Price-to-Net-Cash | 15.12 | |||||
Earnings Yield (Greenblatt) % | 4.28 | |||||
FCF Yield % | 3.62 | |||||
Forward Rate of Return (Yacktman) % | 16.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LMAT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LeMaitre Vascular Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 256.282 | ||
| EPS (TTM) ($) | 2.71 | ||
| Beta | 0.8497 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 0.81 | ||
| Volatility % | 37.98 | ||
| 14-Day RSI | 50.71 | ||
| 14-Day ATR ($) | 3.286796 | ||
| 20-Day SMA ($) | 92.974 | ||
| 12-1 Month Momentum % | 19.79 | ||
| 52-Week Range ($) | 79.005 - 118.01 | ||
| Shares Outstanding (Mil) | 22.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LeMaitre Vascular Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LeMaitre Vascular Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 132 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 131 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 17:00 | In 39 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 38 days | ||
| Goldman Sachs Annual Global Healthcare Conference | 2026-06-10 09:20 | 96.59 (+0.91%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 10:30 | 91.62 (+1.25%) | ||
| General meeting for 2026 | 2026-06-02 10:00 | 91.42 (-2.98%) | ||
| USD 0.250000 Cash Dividend | 2026-05-21 | 101.43 (+0.10%) | ||
| Bank of America Healthcare Conference | 2026-05-13 17:15 | 97.22 (-4.60%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 17:00 | 111.53 (-0.11%) |
Show
Entries
LeMaitre Vascular Inc Frequently Asked Questions
What is LeMaitre Vascular Inc(LMAT)'s stock price today?
The current price of LMAT is $95.56. The 52 week high of LMAT is $118.01 and 52 week low is $79.01.
When is next earnings date of LeMaitre Vascular Inc(LMAT)?
The next earnings date of LeMaitre Vascular Inc(LMAT) is 2026-08-05 Est..
Does LeMaitre Vascular Inc(LMAT) pay dividends? If so, how much?
The Dividend Yield %  of LeMaitre Vascular Inc(LMAT) is 0.94% (As of Today), Highest Dividend Payout Ratio of LeMaitre Vascular Inc(LMAT) was 0.48. The lowest was 0.25. And the median was 0.37. The  Forward Dividend Yield % of LeMaitre Vascular Inc(LMAT) is 1.05%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NAS:LMAT
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on LeMaitre Vascular Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers